ABSTRACT
A series of H-ZSM-5 crystallites with different framework Si/Al ratios was studied by analyzing the kinetics and reaction mechanism of the oligomerization of 4-fluorostyrene as molecular probe reaction for Brønsted acidity. The formation of carbocationic species was followed by UV-Vis spectroscopy. Three carbocationic products were observed, namely a cyclic dimer, a conjugated linear dimer and a larger, more conjugated carbocation. Rate constants for the formation of all three products show a maximum at a Si/Al ratio of 25. Oligomerization of 4-fluorostyrene within the larger supercages of zeolite H-Y leads solely to cyclic dimers. The experimental observations were rationalized by DFT calculations, which show that the selectivity of the styrene oligomerization is controlled by the steric properties of the intrazeolite micropore voids. Two reaction pathways were considered for the formation of the conjugated linear carbocation. The conventional mechanism involves a hydride transfer between two dimeric hydrocarbons (HCs) in the zeolite pores. We propose an alternative monomolecular path, in which the hydride transfer takes place between a hydrogen atom of a dimeric HC and a zeolitic proton, yielding a conjugated carbocation and molecular H(2). Computed free energies indicate that the preference for a particular reaction mechanism is determined by the local shape of the zeolite micropores.
ABSTRACT
The Exubera system (Pfizer, New York, NY/Nektar Therapeutics, San Carlos, CA) is an integration of five major new technologies: protein formulation, powder processing, powder filling, drug packaging, and delivery device. The product provides a simple interface, where the patient interacts only with the delivery device and powder packaging. These components were designed together to assure repeatable dosing when used by a wide range of patients under real-world life-style and handling conditions. The device design is purely mechanical, using patient-generated compressed air as the energy source. Upon actuation, a sonic discharge of air through the novel release unit reproducibly extracts, de-agglomerates, and disperses the inhalation powder into a respirable aerosol. A clear holding chamber allows for patient feedback via dose visualization and separates aerosol cloud generation from the inspiratory effort. The Exubera product was tested under a wide range of typical use conditions and potential misuse scenarios and following long-term usage in clinical trials. These comprehensive characterization programs demonstrated robust aerosol and mechanical performance, confirming the design intent of the inhaler. These studies provide assurance of consistent and reliable dose delivery in a real-world use of the product.
